Jim Beitel Appointed as Chief Business Officer
Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company utilizing its innovative Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies aimed at enhancing treatment for serious diseases, has announced the appointment of Jim Beitel, MBA, as its new Chief Business Officer. This significant move comes at a crucial time for the company, which is dedicated to advancing its promising Cloudbreak DFC pipeline.
Concentration on Cloudbreak Pipeline
In light of recent strategic transactions, Cidara is now focusing exclusively on the opportunities within its Cloudbreak DFC pipeline. The addition of a Chief Business Officer is considered essential for fostering partnerships and exploring licensing opportunities. Preetam Shah, Ph.D., MBA, who previously served as both Chief Financial Officer (CFO) and Chief Business Officer since 2021, will continue in his role as CFO, overseeing finance, accounting, and investor relations.
Leadership Perspectives
Jeffrey Stein, Ph.D., President and Chief Executive Officer of Cidara, expressed his excitement regarding Beitel's appointment, stating, “We welcome Jim to Cidara’s executive team during this pivotal moment of corporate transformation. His extensive experience in biopharma business development and partnerships will be incredibly valuable, especially with the wide-ranging partnering opportunities presented by our Cloudbreak pipeline.” Stein highlighted that the upcoming Phase 2b trial of CD388, which aims to prevent influenza, represents a critical opportunity for the company.
Background and Vision of Beitel
Jim Beitel comes to Cidara with over 20 years of varied experience in the life sciences sector, covering corporate development, strategy, commercialization, and finance across a range of organizations, from biotech firms to large pharmaceutical companies. Previously, he held the position of Senior Vice President of Corporate Development at Fate Therapeutics, where he played a key role in forming strategic partnerships focused on oncology and autoimmune diseases. Reflecting on his new role, Beitel remarked, “I’m excited to join the company at this crucial time. With its Cloudbreak platform and promising pipeline, Cidara is well-positioned to make significant advancements in the treatment of serious diseases, including influenza.”
About Cidara Therapeutics
Cidara Therapeutics is at the forefront of innovation, utilizing its proprietary Cloudbreak platform to create novel drug-Fc conjugates (DFCs). These targeted immunotherapies represent a unique approach, combining small molecules and peptides with a human antibody fragment aimed at specific disease targets while enhancing immune system activity. Based in San Diego, Cidara is dedicated to leveraging this cutting-edge methodology to improve patient care and outcomes for individuals facing severe diseases.
Inducement Awards for Beitel
As part of his appointment, Cidara’s Compensation Committee has provided Beitel with an inducement package that includes a non-qualified stock option award and restricted stock units (RSUs) totaling 71,000 shares of common stock, issued under the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan. This grant features an exercise price that corresponds with the company’s closing stock price and includes a structured vesting schedule over four years.
Contact Information
Investor Contact:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
Media Contact:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
Frequently Asked Questions
1. Who has been appointed as the new Chief Business Officer at Cidara Therapeutics?
Jim Beitel has been appointed as the Chief Business Officer at Cidara Therapeutics.
2. What is the primary focus of Cidara Therapeutics after recent transactions?
Following recent transactions, Cidara is focused primarily on advancing its Cloudbreak drug-Fc conjugate (DFC) pipeline.
3. What role will Preetam Shah continue to hold at Cidara Therapeutics?
Preetam Shah will continue as the Chief Financial Officer overseeing finance, accounting, and investor relations.
4. What is the significance of the Cloudbreak pipeline for Cidara?
The Cloudbreak pipeline is significant as it creates numerous partnering and licensing opportunities that are crucial for the company’s growth and development.
5. How is Jim Beitel’s experience relevant to his new position?
Jim Beitel brings over 20 years of experience in corporate development, focusing on strategy and partnerships, which are essential for the growth and expansion of Cidara's initiatives.
